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Imatinib mesylate (IM) is a tyrosine kinase inhibitor, which inhibits phosphorylation of downstream proteins involved in BCR-ABL
signal transduction. It has proved beneficial in treating patients with chronic myeloid leukaemia (CML). In addition, IM demonstrates
activity against malignant cells expressing c-kit and platelet-derived growth factor receptor (PDGF-R). The activity of IM in the blastic
crisis of CML and against various myeloma cell lines suggests that this drug may also target other cellular components. In the light of
the important role of telomerase in malignant transformation, we evaluated the effect of IM on telomerase activity (TA) and
regulation in various malignant cell lines. Imatinib mesylate caused a dose-dependent inhibition of TA (up to 90% at a concentration
of 15mM IM) in c-kit-expressing SK-N-MC (Ewing sarcoma), SK-MEL-28 (melanoma), RPMI 8226 (myeloma), MCF-7 (breast cancer)
and HSC 536/N (Fanconi anaemia) cells as well as in ba/F3 (murine pro-B cells), which do not express c-kit, BCR-ABL or PDGF-R.
Imatinib mesylate did not affect the activity of other DNA polymerases. Inhibition of TA was associated with 50% inhibition of
proliferation. The inhibition of proliferation was associated with a decrease in the S-phase of the cell cycle and an accumulation of
cells in the G2/M phase. No apoptosis was observed. Inhibition of TA was caused mainly by post-translational modifications:
dephosphorylation of AKT and, to a smaller extent, by early downregulation of hTERT (the catalytic subunit of the enzyme)
transcription. Other steps of telomerase regulation were not affected by IM. This study demonstrates an additional cellular target of
IM, not necessarily mediated via known tyrosine kinases, that causes inhibition of TA and cell proliferation.
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Imatinib mesylate (IM, Gleevec, STI571) belongs to the new
generation of rationalised-developed drugs, aimed against specific
targets in malignant cells. Its original target was the chimeric
protein, BCR-ABL, formed as a result of the molecular juxtaposi-
tion of two genes, BCR and ABL, on a newly created Philadelphia
chromosome in chronic myelogenous leukaemia (CML) patients.
BCR-ABL is a tyrosine kinase, involved in intracellular signalling
pathways leading to proliferation (Capdeville et al, 2002).
However, BCR-ABL is not the only protein kinase that is affected
by the drug. The kinase activity of other receptors – platelet-
derived growth factor receptor (PDGF-R) and the stem-cell factor
receptors (c-kit) Abl and Arg – has been shown to be blocked by
Gleevec as well. The drug has little effect on other kinases
(Kurzrock et al, 2003). However, inhibition of other protein kinase
receptor autophosphorylation was demonstrated in FLT3, CFMC,
c-FMC, v-fms and v-SRC, although at a much higher dosage
(IC50410mM) (Capdeville et al, 2002; Kurzrock et al, 2003).
Autophosphorylation of these protein kinases initiates signal
transduction pathways that control crucial cell functions in
tumorigenesis, including proliferation, adhesion, apoptosis and
differentiation (Heinrich et al, 2002).
c-kit kinase activity is essential for normal haematopoiesis,
melanogenesis, gametogenesis, and growth and differentiation of
mast cells and interstitial cells of Cajal (ICC) (Heinrich et al, 2000).
Active c-kit is present in a variety of malignancies such as germ
line, mast cells, gastrointestinal stromal (GIST) tumours, small cell
lung carcinoma, melanoma, breast cancers, acute myelogenous
leukaemia (AML) and neuroblastoma (Heinrich et al, 2002).
Preclinical studies have shown that c-kit-dependent malignancies
such as GIST demonstrate a reduced proliferation rate after IM
treatment (Capdeville et al, 2002). These findings were corrobo-
rated by reports of clinical response to IM treatment.
Until recently, the clinical activity of IM was attributed solely or
mainly to its tyrosine kinase inhibitory effect. Two lines of
evidence suggest that IM may target other cellular, yet unidentified
components: clinical observations show that patients suffering
from CML respond to the drug even in the blastic crisis stage of the
disease, which is probably caused by other molecular changes
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s(Goldman, 2002). In addition, a recent study describes the
inhibitory effect of IM on various multiple myeloma (MM) cell
lines. The drug is effective in cell lines expressing c-kit, as well
as in those in which the receptor is not expressed (Pandiella et al,
2003).
In the light of the important role of telomerase in malignant
transformation, we surmised that IM’s antineoplastic activity
might be associated with telomerase regulation.
Telomeres are specialised nucleoprotein complexes that protect
against fusion and degradation of linear chromosomes (Blackburn,
2001). A critical shortening of telomeres, associated with each
DNA replication in most normal somatic cells, leads to the
cessation of cell division, a metabolic state called senescence (Kim
et al, 2002). Telomeric dysfunction is associated with very short
telomeres, induces cell ‘crisis’ with chromosomal instability, end-
to-end chromosome fusions, activation of DNA checkpoint
responses, apoptosis and cell death (Blackburn, 2001; Kim et al,
2002). Telomerase is a ribonucleoprotein DNA polymerase
composed of an RNA template (hTR) and a catalytic protein
subunit (hTERT), which is responsible for synthesising the
telomeric repeats (TTAGGG)n at chromosomal ends to compensate
for telomere loss (Kim et al, 2002). The proper functioning of
telomerase requires several other associated proteins (Aisner et al,
2002). The regulation of telomerase is multifactorial, involving
transcriptional and post-translational steps including complicated
gene promoter consisting of binding sites for a variety of
transcription factors, alternative splicing pathways, protein
phosphorylation and dephosphorylation processes. Examination
of the correlation between telomerase activity (TA) and the
expression of hTERT gene or hTR revealed that usually the amount
of hTERT transcript is the limiting factor of its activity (Colgin
et al, 2000). Telomerase post-translational modifications switch the
enzyme from an active form (phosphorylated) to an inactive
protein (dephosphorylated). Phosphorylation of its tyrosine
residues is performed by both PKCa and B or by AKT (protein
kinase B).
Dephosphorylation is performed by protein phosphatase 2A
(PP2A). It has been postulated that phosphorylation and dephos-
phorylation of telomerase is associated with its translocation from
the cytoplasm into the nucleus prior to binding to its telomeric
substrate (Aisner et al, 2002).
It is well established that telomerase upregulation or activation
of alternative mechanisms of telomere maintenance (ALT –
alternative lengthening of telomeres) has a major role in malignant
transformation. If cells are to survive and proliferate indefinitely,
telomere preservation is essential for the immortalisation process
(Collins and Mitchel, 2002). Telomerase activity has been
demonstrated in high levels in over 85% of all malignancies (Shay
et al, 2001). Although telomerase is not an oncogene (Harley,
2002), transfection of hTERT into normal epithelial or endothelial
cells transformed with SV40 large T antigen and N-ras oncogene
allows cells to bypass crisis and ultimately achieve malignancy,
confirming the role of telomerase in cellular immortalisation and
tumorigenesis (Shay et al, 2001).
Therefore, telomerase is considered to be an attractive target in
anticancer therapy. Telomerase inhibition by numerous strategies,
including dominant-negative telomerase mutants (Hahn et al,
1999; Boklan et al, 2002), small molecular weight compounds
(Seimiya et al, 2002), reverse transcriptase inhibitors (Damm et al,
2001), G quadruplex interactive agents (Izbicka et al, 1999; Grand
et al, 2002) and antisense oligonucleotides complementary for hTR
(Herbert et al, 1999, 2002; Akiyama et al, 2003; Pang et al, 2003),
has been shown to limit the growth of immortalised tumour cell
lines by inducing progressive telomere shortening and cell death.
Moreover, a recent report from Moore’s laboratory (Wang et al,
2004) describes the inhibition of MM and non-Hodgkin’s
lymphoma xenografts established from cell lines with short
telomeres, which is associated with increased tumour apoptosis.
In parallel, it is possible that some cytotoxic drugs act via the
inhibition of telomerase, leading to apoptosis. For example, we
have shown that thalidomide downregulates the expression of
hTERT gene in MM cells, via intercalation to its promoter region,
in GC-rich domains that serve as binding sites for SP1 transcrip-
tion factor (Drucker et al, 2003).
Recently, it has been shown that telomerase inhibition achieved
by dominant-negative allele of telomerase (DN-hTERT) sensitises
BCR-ABL-positive leukaemia cells to IM (Tauchi et al, 2002).
However, the effect of IM on TA in c-kit-expressing cell lines has
never been explored. Therefore, we examined the response of TA
and its regulation with reference to IM application in these
settings. Our experimental system includes the SK-N-MC cell line,
an Askin’s tumour cell line, related to Ewing sarcoma lines as well
as several other c-kit-expressing and nonexpressing malignant cell
lines.
MATERIALS AND METHODS
Cell lines
SK-N-MC (Ewing sarcoma) cell line was kindly provided by Dr
Gad Lavie (Sheba Medical Center, Ramat-Gan, Israel). RPMI 8226
(MM cell line) and MCF-7 (breast cancer cell line) were purchased
from the ATCC, USA. HSC 536/N (pro-B-lymphocytes Fanconi C
cells) was donated by Prof. Ina Fabian (Tel Aviv University, Tel
Aviv, Israel). SK-MEL-28, melanoma cells, was given by Dr Britta
Hardy (Felsenstein Medical Research Center, Rabin Medical
Center, Petah-Tikva, Israel). All cell lines were maintained in
RPMI 1640 supplemented with 10–15% heat-inactivated fetal calf
serum (FCS), glutamine (2mM), penicillin and streptomycin (Beit
Haemek, Israel). Ba/F3 and WEHI cells were received from Dr
Drorit Neuman (Tel Aviv University, Tel Aviv, Israel). Ba/F3 cells
were maintained as previously described (Drummond-Barbosa
et al, 1995) in RPMI 1640 supplemented with 10% heat-inactivated
FCS and 10% WEHI conditioned medium as a source of IL-3 and
antibiotics.
All cell lines were c-kit positive, except for Ba/F3, which is
negative for c-kit, BCR-ABL and PDGF-R.
Proliferation assays, apoptosis analyses and TA assays were
performed on all cell lines. SK-N-MC line was chosen for detailed
analysis of various mechanisms related to telomerase regulation.
Proliferation assay
Adherent cells (1 10
4cellsml
 1 SK-N-MC, 9 10
3cellsml
 1
SK-Mel-28) were seeded in quadruplicate in 24-well plates.
Imatinib mesylate (kindly provided by Novartis, NJ, USA) was
added at concentrations ranging from 0 to 20mM. After 3–5 days,
cytotoxicity was determined with the sulphorohodamine B assay
(Skehan et al, 1990). Briefly, cultures were fixed with 10%
trichloroacetic acid (Sigma, Israel) and stained with 0.4 (wv
 1)
sulphorhodamine B (Sigma, Israel) dissolved in 1% acetic acid.
Unbound dye was removed by four washes with acetic acid (1%),
and the dye-stained protein was extracted with unbuffered Tris
base (10mM). The absorbance of stained protein samples was
determined in a 96-well microtitre ELISA plate reader (550nm).
The results obtained with the assay were confirmed by counting
cells in a haemocytometer. The cytotoxicity of all nonadherent
cells (RPMI 8226, HSC 536/N and Ba/F3) was determined using
Trypan blue exclusion assay.
Apoptosis assay
Apoptosis was assessed by detecting DNA fragmentation using the
cell death ELISA kit (Roche, Mannheim, Germany). SK-N-MC cells
(1 10
4) were plated in each well of 24-well plates. Cells were
incubated in the presence of IM (0–15mM). Each treatment was
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sperformed in triplicate. After 5 days, cells were washed once with
phosphate-buffered saline, and 0.5ml lysis buffer was added. After
30min incubation, the supernatant was removed and assayed for
DNA fragments, according to the manufacturer’s instructions. The
absorbance at 405 and 492nm was determined in a computer-
interfaced 96-well microtitre plate reader. Additional plates,
treated as above, were analysed for cell number using the
sulphorhodamine B method. The results obtained from the DNA
fragmentation assay were then normalised for cell numbers.
Results were expressed as relative apoptosis to untreated controls
(enrichment factor).
Alternatively, cells defined by FACS analysis in the pre-G1 stage
of the cell cycle were considered apoptotic.
Cell cycle analysis
Cells (0.7–1 10
4ml
 1) were cultured for 1–5 days. Floating and
adherent cells were combined, washed with PBS and nuclei
prepared from 5 10
5 to 1 10
6 cells for flow cytometric analysis
using a detergent-trypsin method followed by staining with
propidium iodide (Vindelov et al, 1983). DNA content was
analysed by FACSCALIBUR (Becton Dickinson, San Jose, CA,
USA), using ModFitLT cell cycle analysis software (Verity Software
House Inc., Topsham, ME, USA).
Telomeric repeat amplification protocol assay
Measurement of TA was performed by the PCR-based TRAP
assay, using the TRAPEZE telomerase detection kit (Intergene, NY,
USA), according to the manufacturer’s instructions and as
described previously (Kim et al, 1994). Briefly, isolated cells were
incubated with ice-cold CHAPS (3-[(3-cholamidopropyl) dimethy-
lammonio]-1-propane sulphonate) lysis buffer for 30min at 41C
(1 10
6cells100ml
 1) and were subsequently centrifuged at
13000r.p.m. for 30min at 41C. The supernatant was then collected
and the protein concentration was determined by the Bradford
assay (Bio-Rad Laboratories, CA, USA). Protein extract (0.2mg)
was assayed for TRAP analysis. Each reaction was performed in
50ml reaction mixture containing 10 TRAP buffer, dNTP mix, TS
primer, TRAP primer mix and Taq polymerase. Reactions were
performed at 301C for 30min and were then subjected to PCR
amplification for 30 cycles of 941C, 59 and 721C for 30s each, and
were separated by electrophoresis on 12.5% polyacrylamide gels, in
a Mighty Small II gel apparatus (Hoffer Scientific Instruments).
Gels were stained with SYBER
R Green nucleic acid gel stain
(Amresco, Ohio, USA). Quantifications were performed using the
Quantity-one software for Bio-Rad’s Image analysis systems (Bio-
Rad Laboratories). Telomerase activity was calculated according to
the following formula: TPG (U)¼(X–X0)/C:(r–r0)/Cr 100, where
TPG is the total product generated, X signifies non-heat-treated
samples, X0 signifies heat-treated samples, C represents the 36bp
internal PCR control, r is the TSR8 quantification control and r0 is
1 CHAPS lysis buffer control. All results were determined from
at least four to six independent TRAP assays and average activity
was calculated.
RNA purification and RT–PCR analysis for hTERT, PKCa,
AKT 1–3 and PP2A
Expression of the relevant genes was performed by a semiquanti-
tative multiplex RT–PCR technique. Total RNA was extracted
from cells using the Purescript RNA isolation kit (Gentra Systems,
MM, USA) according to the manufacturer’s instructions. RNA
(1mg) was then reverse transcribed into single-stranded DNA
with Superscript
TMII RNase Reverse Transcriptase (Gibco BRL,
England, UK). Each RT–PCR reaction was performed with the
genes’ specific primers as well as b-actin primers as an internal
control. RT–PCR products were separated on 2% agarose gels and
the relative intensity of the amplified products was calculated
compared to the housekeeping gene, b-actin, using the Quantity-
one software for Bio-Rad Image analysis systems (Bio-Rad
Laboratories).
hTERT mRNA was amplified by PCR using the following
primers: forward primer 50-CGGAAGAGTGTCTGGAGCAA-30
(corresponding to GenBank position 1785–1804, accession num-
ber AFO 18167; Poremba et al, 2000) and reverse primer 50-
CTCCCACGACGTAGTCCATG-30 (GenBank position 1961–80).
Amplification was performed with 28 cycles of 941C for 30s,
591C for 30s and 721C for 30s.
Primers for hTERT alternative splicing were: forward primer 50-
GCCTGAGCTGTACTTTGTCAA-30 (corresponding to position
2109–2130, GenBank accession number AF128893/4) and reverse
primer 50-AGGCTGCAGAGCAGCGTGGAGAGG-30 (corresponding
to position 2531–2507) (Yi et al, 2001). Amplification was
performed with 35 cycles of 941C for 20s, 601C for 20s and 721C
for 40s.
The b-actin primer sequences were: forward primer 50-
GACCACACCTTCTACAATGAG-30 and reverse primer 50-GCA
TACCCGTCGTAGATGGGG-30.
The PKCa primers sequences were: forward primer 50-CGAG
GAAGGAAACATGGAACTCAG-30 (corresponding to position
908–926, GenBank accession number X53479) and reverse primer
50-CCTGTCGGCAAGCATCACCTTT-30 (position 1101–1079)
(Oshevski et al, 1999). PCR program for PKCa was 941C for 30s,
571C for 30s and 721C for 30s.
The AKT 1 primers were: forward primer 50-ATGAGC
GACGTGGCTATTGTGAAG-30 (corresponding to position 243–
267, GenBank accession number AF283818) and reverse primer 50-
GAGGCCGTCAGCCACAGTCTGGATG-30 (corresponding to posi-
tions 116–91).
The AKT 2 primers were: forward primer 50-ATGAAT
GAGGTGTCTGTCATCAAAGAAGGC-30 (corresponding to posi-
tion 88–117, GenBank accession number M95936) and reverse
primer 50-TGCCTTGAGGCTGTTGGCGACC-30 (corresponding to
positions 422–402).
The AKT 3 primers were: forward primer 50-ATGAGCGATGT
TACCATTGT-30 (corresponding to position 1–20, GenBank
accession number NM_005465) and reverse primer 50-
CAGTCTGTCTGCTACAGCCTGGATA-30 (corresponding to posi-
tions 327–303) (Nakatani et al, 1999). PCR program for all AKT
isoforms was 30 cycles of 941C for 45s, 551C for 45s and 721C for
45s.
The PP2A primers were: forward primer 50-CCTCTTGTCAT
CAACAGCCGTG-30 (corresponding to position 1296–1317, Gen-
Bank accession number ak097599) reverse primer 50-GCAGGAA
GAACCCACAAAGTG-30 (corresponding to position 2056–2037)
(Luss H et al, 2000). Amplification was carried out with 30 cycles of
941C for 45s, 601C for 45s and 721C for 45s.
All experiments were duplicated and repeated at least three
times.
Western blotting
Phosphorylated AKT was detected in the cells after induction with
FCS as follows: cells were grown in RPMI 1640 medium deprived of
serum for 24h. Imatinib mesylate was then added to the culture for
90min. To induce phosphorylated AKT, FCS was added to the cell
cultures for 1h. Cells were then harvested, washed by PBS and
lysed using the TRAP kit CHAPS lysis buffer. Protein concentra-
tion was determined using the Bradford assay (Bio-Rad Lab.,
Hercules, CA, USA). Identical protein amounts of all samples were
subjected to PAGE. The AKT protein or the phosphorylated form
of AKT protein was detected by specific monoclonal antibody (Cell
Signaling, SC, USA) in 1:1000 dilution, followed by HRP-
conjugated goat anti-rabbit antibody (Jackson Lab., West Grove,
PA, USA). Visualisation of both protein expressions was
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sperformed by the SuperSignal
s West Pico Chemiluminescent
Substrate kit (Pierce, IL, USA) according to the supplied protocol.
Quantification of the signals was performed by using the Quantity-
one software for Bio-Rad Image analysis systems (Bio-Rad
Laboratories). Phosphorylated AKT expression was calculated
relative to the total signal obtained from the AKT protein.
Nuclear localisation of hTERT
Localisation of telomerase was analysed in two ways: in situ TRAP
assay and immunofluorescence. In situ TRAP assay was performed
as described previously (Ohyashiki et al, 1997). Cells were
mounted on silane-coated slides and subjected to TA reaction in
the presence of 20mM Tris-HCl (pH 8.3), 1.5mM MgCl2,6 3 m M
KCl, 0.05% Tween 20, 1mM EGTA, 50mM deoxynucleoside
triphosphatase, bovine serum albumin (BSA) (0.1mgml
 1), 1mg
T4 gene protein (Boehringer Mannheim, Germany), 2U Taq
polymerase and 10pmol FITC-labelled TS forward primer (50-
AATCCGTCGAGCAGAGTT-30; Metabion, Germany). Slides were
incubated for 30min at 221C in the dark. After TS extension, 25mM
of the same solution was mixed with 10pmol of FITC-labelled CX
reverse primer (50-CCCTTACCCTTACCCTTACCCTTA-3; Metabion,
Germany). Samples were then heated to 901C for 1.5min to
inactivate the telomerase, and then amplified in PCR thermal
cycler (Eppendorf). PCR conditions were 30 cycles of 941C for 30s,
501C for 30s and 721C for 90s. Slides were washed with PBS, sealed
with mounting medium containing DAPI (Sigma, Israel) for
nucleus counterstain and observed under a fluorescence micro-
scope (Olympus). The presence of FITC dots in the nucleus
reflected TA.
For immunofluorescence analyses, cells were grown in Lab-Tek
Chamber Slides
TM system (Nalge Nunc International Corp., USA),
washed and fixed with PFA buffer (4% paraformaldehyde in PBS
with 0.5% Triton X-100) for 30min. Cells were then washed with
0.5% Triton X-100 in PBS and blocked with 4% BSA and 0.5%
Triton X-100 in PBS for 30min. Subsequently, cells were incubated
with 1:20 antitelomerase antibody (mouse monoclonal antibodies,
Novocastra Laboratories, England, UK) in blocking buffer for 2h.
After washing with PBS, cells were incubated in blocking buffer
containing FITC (goat anti-mouse fluorescein conjugated, Chemi-
con International, CA, USA) as secondary antibody (1:20) and
anti-nucleolin antibody (c23, Santa Cruz Biotechnology, CA, USA)
conjugated to TRITC (1:10) for 30min. Cells were stained with
DAPI in a mounting medium (Vector Laboratories, England, UK)
to counterstain the nucleus. An Olympus microscope with
appropriate filters was used. Images were collected and processed
using Olympus DP-software.
DNA polymerisation reaction
The nuclear fractions were tested for DNA synthesis with defined
DNA–DNA template primers with the following sequence:
50-ATTTCACATCTGACTT-30
30-CCTAAAGTGTAGACTGAATTGTTTGGCGGA-50
The primer was end-labelled at the 50 end with T4 polynucleo-
tide kinase (purchased from MBI, Fermentas, Germany) and
[g-
32P]ATP. The end-labelled primer was annealed to the template
DNA as described (Bakhanashvili and Hizi, 1992).
The DNA polymerisation reactions contained 10mM Tris-HCl
(pH 7.5), 2mM DTT, 10mM MgCl2, 100mM dNTP (Pharmacia
Biotech, Uppsala, Sweden), 0.1mgml
 1 BSA and 50-end-labelled
DNA/DNA template-primer. The reaction was started by the
addition of 10mg nuclear extract. Assays were carried out at 371C
for 10min. Aliquots (5ml) were removed into 5ml of formamide
dye mix, denatured at 1001C for 5min and cooled on ice.
Electrophoretic analyses were performed in 16% polyacrylamide
sequencing gels followed by autoradiography. The results were
reproduced three times using separate preparations of nuclear
extracts.
RESULTS
Effect of IM on the proliferation of SK-N-MC cells
The effect of IM on cell growth was determined using the SRB
assay. Figure 1 describes a dose-dependent growth inhibitory
effect. A 50% reduction in cell numbers was achieved by 15mM IM
administration. Therefore, concentration of 15mM was chosen for
further experiments.
Apoptotic effect of IM on SK-N-MC cells
In order to determine whether imatinib has an apoptotic effect on
SK-N-MC cells, we analysed them for DNA fragmentation using
the cell death detection ELISA method. Cells exposed to IM at 10
and 15mM demonstrated enrichment factor values of 119 and 128.5,
respectively, compared to 100 as controls, which correspond to less
than 10% apoptosis. These values suggest that IM treatment had
no significant apoptotic effect on SK-N-MC cells. Similar results
were obtained when pre-G1 phase of the cell cycle was analysed by
FACS (not shown).
Cell cycle analysis
To explore whether IM exerts its antiproliferative effect via cell
cycle arrest, we determined the cell cycle status of the treated cells,
compared to the controls. Imatinib mesylate caused changes in cell
cycle status, which were most prominent in days 4 and 5. As shown
in Table 1, IM treatment resulted in the arrest of cells in G2/M
phase of the cell cycle. This arrest was accompanied by a decrease
in the accumulation of cells in the S phase.
Telomerase activity levels after IM treatment
SK-N-MC Ewing sarcoma cells were exposed for 5 days to 10–
15mM IM, the concentration shown to cause 35–65% growth
inhibition, respectively. Telomerase activity was assessed using the
TRAP assay, as described in Materials and Methods. The activity of
telomerase was reduced in a dose-dependent manner and
compared to its activity in the untreated control cells (Figure 2A
and B). Imatinib mesylate at 10mM led to 35% TA inhibition,
whereas 15mM caused about 75% inhibition. To examine whether
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Figure 1 Growth inhibition of SK-N-MC cells by imatinib after 5 days.
Cells were grown in the presence of imatinib at 0–20mM for 5 days and
their proliferation was calculated by the SRB method. The graph represents
five independent experiments conducted in duplicate.
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sthe downregulation of TA was a nonspecific result of reduced
proliferation, highly enriched nuclear fractions of treated and
nontreated cells were analysed for DNA polymerisation activity of
DNA polymerase a, a major nuclear enzyme. The results obtained
revealed that there was no decrease in DNA polymerase capacity of
the nuclear enzyme (not shown), thus indicating a specific effect of
the drug on TA. Figure 2C shows the gradual effect of IM on TA
over time. In the first 3 days after the addition of the drug, the
activity of the enzyme was reduced to about 85% compared to
controls. After 4 days, only 50% of the initial TA was detected. The
inhibition reached its maximal level after 5 days, when approxi-
mately 80% of TA was abolished.
To clarify whether telomerase inhibition is mediated by direct
interaction of the drug with the enzyme, we added IM at 15mM to
SK-N-MC cell lysates 30min prior to TRAP assay. Imatinib
mesylate had no effect on TA in these settings (not shown).
Regulation of hTERT
Telomerase is known to be regulated both transcriptionally and
post-translationally (Aisner et al, 2002).
Transcriptional regulation of hTERT hTERT expression is
regulated by the activity of its promoter, modulated by numerous
transcription factors and by alternative splicing. We analysed
telomerase expression at both levels.
Expression of hTERT total mRNA: We determined the expres-
sion of hTERT 24, 48, 72 and 96h following cellular exposure to
IM. The expression of the gene was evaluated relative to the
expression of the b-actin, a housekeeping gene.
Analyses of hTERT mRNA levels in treated cells compared to
untreated cells by RT–PCR revealed a consistent decrease in its
expression. The decrease ranged between 15 and 30% and was
similar at 10 and 15mM concentrations, as well as at all time points
(Figure 3A and B).
Alternative splicing of hTERT: hTERT gene possesses six
different alternative splicing forms, in which four contain deletions
and two contain insertions of the gene. Only the full intact
transcript can be translated into a properly active enzyme.
Examination of hTERT alternative splicing forms showed that
there was no difference between the various transcripts in the
treated compared to the nontreated cells (Figure 3C). The analysis
was carried out using primers that are complementary to the two
regions of deletions (named a and b), to amplify four expected
alternative forms of hTERT transcript.
Post-translational modification of telomerase The other level of
telomerase regulation is post-translational. The enzyme becomes
active upon phosphorylation, but inactive following dephosphory-
lation. We analysed the expression of the enzymes known to be
involved in these modifications.
Phosphorylation by PKCa and AKT: Telomerase is phosphory-
lated by the two kinases AKT and PKCa. To determine whether its
enzymatic activity was inhibited through modulation of its
phosphorylation status, the possible direct effect of IM treatment
on the phosphorylated form of AKT was monitored by Western
blot analysis on SK-N-MC-treated cells using specific AKT or
phospho-AKT antibodies. As can be seen in Figure 4, the amount
of phosphorylated AKT decreased dramatically after exposing the
cells to 15mM IM for 90min. Imatinib mesylate caused 72%
reduction in the phosphorylated form of AKT.
In addition, the expression of the genes encoded for AKT and
PKCa was monitored. The AKT kinases appear in three forms:
AKT 1, 2 and 3. RT–PCR revealed no changes in the expression of
AKT 2 or AKT 3 (not shown). However, there was a tendency for
expression of AKT 1, the third AKT form, to be inhibited (Figure
5A and B).
The average decrease in AKT 1 expression was about 25%.
RT–PCR analyses of PKCa expression showed no change in its
expression in response to IM treatment (not shown).
Dephosphorylation by PP2A: As TA is dependent on its
phosphorylation status, dephosphorylation abolishes its activity.
The expression of PP2A in SK-N-MC cells exposed to IM was
followed by RT–PCR. Increase in its expression was seen mainly
Table 1 Cell cycle analysis after treatment with imatinib
Time (days) Treatment %G0/G1 %S %G2/M
4 Control 60.3372.3 35.5274.4 3.2674.3
15mM IM 58.0172.2 26.8872.5* 15.171.1*
5 Control 60.2874.9 28.773.9 9.571.6
15mM IM 68.3573.0* 22.1373.6* 11.9571.8*
IM¼imatinib mesylate. *P-value o0.05.
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Figure 2 Telomerase activity in SK-N-MC cells treated with imatinib.
(A) Telomeric repeat amplification protocol assay describing TA (one
representative experiment). Imatinib concentrations are indicated above.
R8: internal PCR control; N: negative control. (B) Quantification of TA
affected by 15mM imatinib (average of four independent assays). (C)
Kinetics of TA affected by imatinib.
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s24 and 48h after IM treatment. However, this increase was reduced
after 72 and 96h of IM exposure, compared to the expression of
the control housekeeping gene in the nontreated cells (Figure 5C
and D).
Subnuclear localisation of telomerase
Recently, Collins et al reported another important aspect of
telomerase regulation (Wong et al, 2002). In their study, they
showed the significance of the telomerase subnuclear localisation,
which affects its activity. Localisation of the enzyme in the
nucleolus, away from its natural telomeric substrate, results in a
nonactive telomerase. Its activity is restored when it is in the
nucleoplasm, close to the telomeres. Therefore, we determined its
localisation after IM treatment. Localisation of telomerase was
examined in two different ways: firstly, by in situ TRAP assay,
using fluorescent primer as its substrate and, secondly, by double
staining of telomerase and nucleolin, a protein that is typical of
nucleoli. There was no difference in the localisation of telomerase
between treated and nontreated cells, as its presence was detected
in the nucleoli as well as in the whole nucleoplasm (Figure 6).
Effect of IM on growth and TA in other cell lines
The following cell lines expressing c-kit were tested for their
growth response to the drug: HSC 536/N, pro-B-lymphocytes
Fanconi C cells; RPMI 8226, MM cells; SK-MEL-28, melanoma
cells; MCF-7, breast cancer cell line. All the cells expressing c-kit
responded to IM at the same range of dosage, 10–20mM. The drug
caused about 50% decrease in proliferation, and a differential
inhibition of TA (Figure 7). In one cell line, SK-MEL-28, the native
TA in control cells was low compared to the other cell lines, and
the effect of the drug on its activity was much less pronounced
(inhibition of about 20%). The latter’s effect may be correlated
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Figure 3 Transcription regulation of hTERT in SK-N-MC cells exposed to imatinib. hTERT expression was evaluated by RT–PCR, using primers
homologous to the total gene transcript. The alternative spliced variants were amplified using primers homologous to the two splice sites of the gene mRNA
molecule, namely a and b.( A) An example of hTERT total transcript expression (after 72h of imatinib treatment). (B) Quantification of the hTERT
expression (an average of four experiments). (C) Alternative splicing of hTERT (after 72h of imatinib treatment). Sizes of the various splice forms are
indicated on the right. M: molecular size marker.
Control cells
P-AKT
AKT 
Imatinib-treated cells
Figure 4 Phosphorylated AKT expression in response to imatinib
treatment. Phosphorylated AKT and total AKT protein levels after SK-N-MC
exposure to imatinib were analysed by Western blotting, as described in
Materials and Methods.
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swith the low level of TA in these cells, reflecting a lesser
proliferative dependency on TA.
We then explored the effect of IM on pro-B cell line, Ba/F3,
which does not express any of the known tyrosine kinase receptors
(BCR-ABL, c-kit or PDGFR). Treatment with 10mM IM for 3 days
resulted in the inhibition of proliferation (65%) and TA (50%).
Administration of 15mM IM for 5 days reduced the proliferation
and TA by 50% and more than 95%, respectively (Figure 8). These
data suggest that the downregulation of TA caused by IM is not
necessarily c-kit dependent.
DISCUSSION
Telomerase is an unusually challenging target for anticancer drug
development as it is intrinsic to the proliferation capacity of cancer
cells. Over 90% of tumour cells express active telomerase, yet
somatic cells rarely possess its activity. Due to its remarkable
importance in the biology of malignancy, the effects of various
drugs on its activity are of potential importance.
Our results demonstrate the ability of IM to inhibit TA in cell
lines independently of c-kit expression. More specifically, a
marked decrease of TA was demonstrated in SK-N-MC cells
(Ewing sarcoma cells), as well as other cell lines expressing c-kit
including HSC 536/N (Fanconi anaemia cells), SK-MEL-28
(melanoma cells), RPMI 8226 (MM cells) and MCF-7 (breast
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Figure 5 hTERT post-translational modifications: expression of hTERT
kinase, AKT 1, and hTERT phosphatase, PP2A, in response to imatinib
treatment at various concentrations. The expression of both genes was
monitored by RT–PCR. (A) Levels of AKT 1 mRNA in response to various
concentrations of imatinib. (B) Quantification of AKT 1 mRNA. (C)
Expression of PP2A analysed by RT–PCR (an example of expression after
3 days is shown). M: molecular weight marker. (D) Quantification of PP2A
expression (an average of four independent experiments is shown).
A
B
Figure 6 Subnuclear localisation of hTERT in response to imatinib. SK-
N-MC cells were exposed to 15mM imatinib for 5 days, and stained with
FITC-conjugated anti-telomerase antibodies as described in Materials and
Methods. (A) Control cells. (B) Cells treated with imatinib.
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scancer cells). Telomerase activity was also inhibited to the same
extent in ba/F3 (murine pro-B cells), in which the c-kit receptor (or
BCR-ABL or PDGF-R) is not expressed. This inhibitory effect was
specific to telomerase, as the drug did not affect a different DNA
polymerase, DNA polymerase a.
The effect of IM on cell proliferation was quite similar in cells
expressing or nonexpressing c-kit. The drug inhibited 50% of
cellular proliferation at a concentration of about 15mM. This is in
agreement with a previous study, which demonstrates the same
dosage response of 10–15mM for other Ewing sarcoma cell lines
(Merchant et al, 2002). Notably, MM cells responded to the drug
at similar concentrations (Pandiella et al, 2003). BCR-ABL-positive
human leukaemia cell lines such as K562, KU812, MC-3, NMBA-1,
KBM-5, Z-33, Z-119, Z-181, human glioma cells (U-87, U-343) and
human GIST (GIST882) are more sensitive to IM (Capdeville et al,
2002). It seems likely therefore that the antiproliferative effect of
IM is tumour specific.
Moderate changes in the cell cycle were detected: a decrease of
S phase of the cell cycle accompanied by a partial cellular
accumulation in G2/M phase. Interestingly, similar effects on the
cell cycle were also reported by others, differing according to the
receptor involved in the drug response. A decrease in the
proliferation of breast cancer cell lines was associated with a
growth arrest at G2/M phase of the cell cycle, a signal that was
probably mediated by c-kit (Roussidis et al, 2004). Two other
reports described a different effect of IM on cell cycle –
accumulation of cells mainly in G0/G1 phase – in haematological
cell lines expressing BCR-ABL (Nishimura et al, 2003; Yin et al,
2004).
Recent studies have indicated that telomerase plays a key role in
cellular resistance to apoptosis (Fu et al, 1999). Interestingly, IM
treatment did not induce apoptosis in all cell lines tested in our
study. This finding is in accordance with a recent study conducted
on K-562, a BCR-ABL-positive cell line, exposed to IM. The
authors demonstrated that IM induced a caspase-independent,
necrosis-like cell death mediated by the serine protease activity of
Omi/HtrA2 (Okada et al, 2004). Other studies demonstrated an
inhibitory effect of IM on PDGF-R-expressing cell lines, suggesting
that this effect was mediated mainly through promoting growth
arrest rather than apoptosis (Kilic et al, 2000). Although most of
telomerase inhibition strategies resulted in decreased proliferation
and apoptosis or cell cycle arrest (Hahn et al, 1999; Herbert et al,
1999; Heinrich et al, 2000; Kilic et al, 2000; Boklan et al, 2002;
Seimiya et al, 2002; Zaffaroni et al, 2002), other studies showed
that inhibition of telomerase was accompanied mainly by the
inhibition of cell proliferation rather than cell death. For example,
hTR antisense inhibited TA in human pancreatic carcinoma cell
line, concomitantly with a significant decrease in proliferation,
without a crisis or senescence phenomenon (Teng et al, 2002; Teng
and Fahey, 2002). In another study, histone deacetylase inhibitors,
which suppress hTERT expression in prostate cancer cells, also
inhibited cell proliferation inhibition with no cell cycle arrest,
apoptosis or cell differentiation (Suenaga et al, 2002). The results
of our study show that IM inhibits proliferation by cell cycle arrest
and not by apoptosis.
Telomerase activity is regulated on multiple levels (Cong et al,
2002). Its regulation includes transcription, mRNA splicing,
maturation and modifications of hTR and hTERT, transport and
subcellular localisation of each component, assembly of the
holoenzyme to an active ribonucleoprotein, accessibility and
proper function on its telomeric substrates (Cong et al, 2002).
Our results show that IM downregulates TA by two separate
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Figure 7 Imatinib inhibits proliferation and TA in various cell lines.
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Figure 8 Telomerase activity in cells not expressing c-kit. Ba/F3 cells
were exposed to imatinib at the indicated concentrations for 3 days, and
TA was analysed by the TRAP assay. (A) An example of TRAP assay
results. R8: internal standard of the TRAP assay; N: negative control with
no cell extract. (B) Quantification of telomerase inhibition by imatinib.
Telomerase activity in the treated cells is shown as a percentage of control
values.
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smechanisms, operating at different time points. The most
prominent effect was a marked dephosphorylation of the AKT
protein, which is one of the major kinases that phosphorylate
telomerase in the cell. The other kinase that may phosphorylate
telomerase is PKCa or PKCx. Although we did not test the levels of
phosphorylated PKC in our study, it is reasonable to suppose that
the drug does not affect PKC phosphorylation. Initially, IM was
selected as a PKC inhibitor. However, modifications on the original
compound abolished its inhibitory activity against PKC completely
(Bakalova et al, 2003). Imatinib mesylate cellular effects are
mediated specifically via downregulation of phosphorylation forms
of AKT (Heinrich et al, 2000) as well. Our results are in keeping
with the known mechanism of effects of IM on intracellular signal
transudation pathways. hTERT expression was reduced up to 30%
after IM treatment, which is considered to be moderate. There was
no change in the alternative splicing patterns of hTERT expression
as a result of IM treatment. Post-translational changes of
telomerase were also monitored indirectly, by evaluating the
expression of the enzymes involved in telomerase phosphorylation
and dephosphorylation. RT–PCR analysis revealed a slight
decrease in AKT 1, which phosphorylates telomerase, and no
changes in the other forms of AKT expression or PKCa. The
expression of PP2A, which deactivates telomerase by dephos-
phorylation, was increased by 20–30% in treated cells compared to
untreated. Together, these results suggest that IM reduced TA
mainly via its post-translational modification – a decrease in the
phosphorylation form of the enzyme. Recently, another way of
telomerase regulation was demonstrated, concerning its sub-
nuclear localisation (Wong et al, 2002). The authors showed that
the enzyme activity corresponds to its localisation in the
nucleoplasm, probably close to its telomeric substrates. Upon
inactivation, it is sequestered into the nucleoli. No difference in
telomerase subnuclear localisation between treated and nontreated
cells was found in this study.
We detected two phases of TA inhibition. Immediately after the
drug addition, there was a moderate decrease (B15%), which
lasted 3 days. At days 4 and 5, the inhibition reached its maximal
level, that is, 75–80%. These results attest to multiple levels of
telomerase inhibition. Decreased expression of telomerase post-
translational modifying enzymes (AKT 1) and the slight increase in
telomerase dephosphorylating enzyme, PP2A, should be effective
during 24h after drug addition. However, downregulation of the
phosphorylated form of AKT, which will eventually decrease the
phosphorylated form of telomerase, should be detected only after
3 days, due to the long half-life of the enzyme. Similarly, inhibition
of transcription may also be detected at a similar time point, by the
same reason. Therefore, we hypothesise an accumulative effect on
telomerase regulation in these settings: mainly post-translational
modification and also a minor transcriptional regulation.
Our results support other studies, establishing possible links
between TA and c-kit, which is via the ERK signal transduction
pathway. Preclinical studies have established that IM blocks c-kit
autophosphorylation, as well as SCF-mediated downstream
cascades such as activation of ERK1, ERK2 and AKT, all of which
belong to the MAP kinase family (Buchdunger et al, 2000; Heinrich
et al, 2000). The effect of IM on non c-kit-expressing cells suggests
that telomerase inhibition may be mediated by other mechanisms
as well. Support for the notion comes from a recent study
describing a panel of pancreatic cell lines, all of which are
responsive to IM, in a nondependent c-kit, PDGF-R or BCR-ABL
pathways. The authors show that c-kit and PDGF-R do exist in
these cells, but the response to IM was mediated by other yet
unknown pathways (Li et al, 2003). Our future work is directed
around this issue, in order to clarify possible mechanism(s) by
which IM downregulates TA in cells, lacking the known tyrosine
kinase targets of IM.
Telomerase activity in general is associated with cellular
proliferation. Inhibition of telomerase may lead to proliferation
arrest in two ways: by eroding telomeres, which will eventually
become too short to allow proper cellular division, and by a more
direct effect on the telomere distal end, in which the enzyme no
longer protects, thereby leading to immediate proliferation arrest.
Shortening of telomeres as a result of different telomerase
inhibitors leading to cellular senescence and apoptosis has been
demonstrated in several reports (Hahn et al, 1999; Herbert et al,
1999, 2002; Izbicka et al, 1999; Damm et al, 2001; Boklan et al,
2002; Grand et al, 2002; Seimiya et al, 2002; Pang et al, 2003). The
other protective function of telomerase, proposed by Blackburn
and her group, was named ‘telomeres capping’ (Chan and
Blackburn, 2002). A concomitant inhibition of telomerase and
alteration in the expression of AKT 1 and PP2A were detected 24h
following IM treatment. The proliferation arrest observed in our
study might be mediated by disrupting the capping ability of
telomerase, thus exposing the telomeres with no protection,
leading to proliferation arrest. Alternatively, these two processes,
telomerase inhibition and cellular senescence, may act in parallel.
The variable telomerase inhibition accompanied by about 50%
inhibition of cellular proliferation in the various cell lines may
support these dynamics. Accordingly, dissociation of TA and
proliferation was demonstrated in human HaCaT skin keratino-
cytes, in which TGF-b1 downregulated c-myc, TA and cellular
proliferation. Overexpression of hTERT in these settings restored
TA but not proliferation (Cerezo et al, 2002).
Since TA is typical of over 90% of human tumours, and is absent
in most somatic cells, its inhibition represents a novel therapeutic
strategy. This inhibitory effect may be enhanced by their
combination with other conventional cytotoxic drugs (Wang
et al, 2004). Two concerns have been mentioned regarding
telomerase inhibition. Firstly, it may result in damage to normal
stem cells. However, the length of telomeres in these cells
compared to malignant cells may protect them from that apparent
damage. Secondly, inhibiting TA might result in genomic
instability, thereby leading to increased neoplasia (Artandi et al,
2000). This idea is based on the increased neoplasia in mTR / 
knockout mice, mostly in P53 mutant cells. However, that risk
might not be relevant since mice telomere dynamics is significantly
different from that of humans (Wright and Shay, 2000).
In summary, we hereby demonstrate an additional mechanism
relating telomerase inhibition and reduced cell proliferation, not
necessarily mediated via the known tyrosine kinase targets of IM.
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